Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Change in Receivables (2016 - 2025)

Gyre Therapeutics (GYRE) has disclosed Change in Receivables for 12 consecutive years, with $4.8 million as the latest value for Q4 2025.

  • Quarterly Change in Receivables rose 321.03% to $4.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4.5 million through Dec 2025, up 1423.3% year-over-year, with the annual reading at $10.8 million for FY2025, 105.55% up from the prior year.
  • Change in Receivables for Q4 2025 was $4.8 million at Gyre Therapeutics, up from $1.1 million in the prior quarter.
  • The five-year high for Change in Receivables was $4.8 million in Q4 2025, with the low at -$2.3 million in Q1 2021.
  • Average Change in Receivables over 5 years is $152555.6, with a median of -$564000.0 recorded in 2022.
  • The sharpest move saw Change in Receivables crashed 158.45% in 2022, then surged 321.03% in 2025.
  • Over 5 years, Change in Receivables stood at $704000.0 in 2021, then crashed by 180.11% to -$564000.0 in 2022, then plummeted by 163.3% to -$1.5 million in 2023, then surged by 177.17% to $1.1 million in 2024, then skyrocketed by 321.03% to $4.8 million in 2025.
  • According to Business Quant data, Change in Receivables over the past three periods came in at $4.8 million, $1.1 million, and -$1.5 million for Q4 2025, Q4 2024, and Q4 2023 respectively.